Indian Scientists Develop Nano-Formulation for Safer Parkinson’s Treatment

New Delhi: Scientists at the Institute of Nano Science and Technology (INST), Mohali, an autonomous institute under the Department of Science and Technology, have announced a breakthrough in Parkinson’s treatment through a novel targeted nano-formulation. The formulation facilitates the sustained release of 17beta-oestradiol, a hormone critical for managing Parkinson’s disease and other neurodegenerative disorders linked to hormonal imbalances in the brain.

Published in Carbohydrate Polymers, the study highlights the use of Dopamine Receptor D3 (DRD3) conjugated with 17beta-oestradiol-loaded chitosan nanoparticles, allowing targeted delivery of the hormone to the brain. This innovative approach minimizes peripheral side effects associated with 17beta-oestradiol therapy and addresses challenges in understanding its molecular mechanisms for neuroprotection.

The researchers noted that the nano-formulation effectively protected neurons by inhibiting the mitochondrial translocation of calpain, a protein responsible for mitochondrial damage in Parkinson’s. The targeted delivery system also restored mitochondrial homeostasis by preventing the degradation of BMI1, a key regulator of mitochondrial function and a newly identified substrate of calpain.

In rodent models, the nano-formulation alleviated behavioral impairments associated with Parkinson’s, showcasing its potential as a safer and more effective therapeutic option. The study underscores the role of 17beta-oestradiol in managing oxidative stress in Parkinson’s patients, offering a promising pathway for improving treatment outcomes with further exploration of long-term safety and delivery mechanisms.

Previously, INST researchers demonstrated the therapeutic potential of melatonin-based nano-formulations for Parkinson’s. This new advancement adds to the growing arsenal of nano-technological innovations targeting neurodegenerative disorders. Parkinson’s disease, caused by the degeneration of dopamine-secreting neurons and protein aggregation in the brain, remains a challenge as current treatments only address symptoms without offering a cure.

This marks a significant step forward in neurotherapeutic research, emphasizing the role of advanced nanotechnology in addressing unmet medical needs. By focusing on hormone-based interventions and targeted drug delivery, the study opens up new possibilities for reducing side effects and enhancing the efficacy of treatments for Parkinson’s and similar disorders. With ongoing research to refine these formulations and ensure long-term safety, this innovation can potentially transform patients' quality of life, offering hope for more effective management of progressive neurological conditions.